• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Oschmann to chair Merck’s executive board

Oschmann to chair Merck’s executive board

October 14, 2015
CenterWatch Staff

Germany-based Merck has appointed Stefan Oschmann as new chairman of the executive board and CEO. The appointment will take effect with the end of the Annual General Meeting on April 29, 2016. Oschmann will succeed Karl-Ludwig Kley, who will retire after nine years as head of Merck.

Oschman has been a member of the executive board since 2011. He was initially in charge of the pharma business before being appointed as deputy chairman of the executive board and deputy CEO at the beginning of 2015, responsible for strategy and innovation.

Prior to joining Merck, Oschmann worked for more than 20 years for U.S. pharma company Merck Sharp & Dohme. He is president of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and vice president of European Federation of Pharmaceutical Industries and Associations (EFPIA).

Kley already had been a member of the supervisory board of Merck and the board of partners of E. Merck since 2004. In 2006 he became deputy chairman of the executive board of Merck before taking over as chairman in 2007. Previously, he was chief financial officer at Deutsche Lufthansa for eight years and joined the airline’s supervisory board in 2013. In addition, he is vice president of the German Chemicals Association (VCI) and a member of the steering committee of the Federation of German Industries (BDI).

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing